The Lump That Arrives Months Later
Most filler complications announce themselves while the patient is still in the chair. Swelling, bruising, blanching, an asymmetry that was not there ten minutes ago — all of it happens inside the appointment, where you can see it.
Delayed-onset nodules do not behave like that. They appear weeks or months after an uneventful treatment, in a patient who was discharged happy, and frequently in front of a clinician who did not perform the injection and has no record of what was used. That last detail changes the problem more than anything about the nodule itself.
What follows is about recognition and sorting rather than treatment. The treatment decisions belong to the clinician who has examined the patient; the part that travels is knowing what you are looking at, and what it would cost to guess.
A different problem from the one you were trained for
Early nodules are usually mechanical. Product placed too superficially, too much in one plane, a lump you can feel on the day and often address on the day. The mental model most injectors carry is built from those, and it is a poor guide to what arrives later.
Late inflammatory reactions present differently — typically as tender, erythematous swelling at or around previous injection sites, sometimes bilateral, sometimes involving product that has been quietly in place for a year [1]. The distribution is the clue. A reaction that appears simultaneously at several sites treated on different occasions is telling you something about the patient's immune state — not about your technique on any one of those days.
The interval is the other clue, and it is the one that misleads. A patient who was well for eight months does not connect a new swelling to a treatment they have stopped thinking about, so the history you get will often begin with the swelling rather than with the injection. You have to go looking for the treatment, and the further back it sits, the less reliable the account of it becomes.
The trigger is usually somewhere else
The reported precipitants are strikingly ordinary. Viral and bacterial illness, dental work, and vaccination all recur in the case literature, with the common thread being a systemic immune event rather than anything local to the face [1][2]. A series of cases following COVID-19 vaccination attracted particular attention, and the authors proposed a mechanism involving angiotensin-converting enzyme pathways to explain both the reaction and the response they observed to treatment [3].
That proposed mechanism is worth holding loosely. It is a hypothesis built to fit a small number of cases, published as case reports, and it has not been tested in a way that would let anyone claim it as established. The clinically useful part is not the mechanism at all — it is the observation that asking a patient with a new nodule what has happened to them systemically in the preceding fortnight is more likely to be informative than asking what was injected.
The differential is the whole job
The hard part is that a late inflammatory reaction, a low-grade biofilm infection and an acute bacterial infection can look similar at first presentation, and they do not want the same response. Reaching for hyaluronidase because the swelling is at a filler site is the intuitive move, and in an infected field it is the wrong one — it can disperse organisms rather than resolve the problem, and it removes the chance to culture before anything is changed [2][4].
Consensus guidance on complication management works through this as a sequence rather than as a single decision, and the sequence puts characterising the lesion before intervening on it [2]. That ordering is the substance of the recommendation. It is also the thing most likely to be skipped by a practitioner who wants the patient to stop being unhappy in their waiting room.
There is a second reason the order matters, and it is not clinical. Once the enzyme has been given, the picture you would have used to work out what was happening has gone — and so has the ability to say, later, what the lesion looked like before anyone touched it. That is a problem for the patient's next clinician and, if the case goes anywhere, for you. Acting early feels like decisiveness. In this particular presentation, it is more often the destruction of your own evidence.
What the evidence does not establish
Almost everything in this area rests on case reports, case series and consensus opinion. Incidence is one of the weakest parts: the reported rates come from cohorts assembled in different ways, using different definitions of what counts as a delayed nodule, over different follow-up periods, which is why the published figures vary by an order of magnitude and none of them should be quoted to a patient as a risk [1][5].
The product question is similarly unsettled. Delayed nodules have been described across manufacturers and cross-linking technologies, and a well-documented series in one specific filler [5] does not establish that the product was causative rather than simply the one being studied. Nobody has run the trial that would separate product effect from patient susceptibility, and it is not obvious that anyone could.
The patient is often not your patient
This is the practical asymmetry that makes late reactions different. The person presenting may have been treated elsewhere, months ago, by someone they no longer wish to contact, and they may genuinely not know what was used or whether it was hyaluronic acid at all. A permanent or semi-permanent product changes the entire assessment, and a patient's recollection of "filler" is not evidence of anything.
Consensus recommendations are consistent that the batch record and product identity belong in the notes for exactly this reason [4]. That is a duty owed to a clinician you will never meet, several years from now, who will be trying to work out what is under the skin of someone sitting in front of them.
It also changes what you can safely say. A practitioner who assumes hyaluronic acid, treats on that assumption and turns out to be wrong has not made a defensible error — they have made an unforced one, because the uncertainty was visible from the start. Where the product cannot be established, saying so to the patient and referring on is a clinical decision rather than an admission of inadequacy, and it reads that way in a record too.
What this changes in the consultation
Ask about the fortnight, not the injection. Recent illness, dental treatment, vaccination and any new systemic symptom are more likely to explain a late nodule than anything about the original appointment. Ask before you examine, so the answer is not shaped by what you have already found.
Establish what is under the skin before deciding anything. If the product is unknown or possibly not hyaluronic acid, the reversibility you are relying on may not exist. An unknown product is a reason to slow down, not a reason to try the enzyme and see.
Separate infection from inflammation before you treat either. Fluctuance, systemic upset, rapid progression and a discharging lesion belong in a different pathway from a firm, tender swelling that has been present for a fortnight. If you cannot tell, that uncertainty is itself the finding, and it points outward rather than to a syringe.
Tell the patient the timeline honestly. These reactions frequently take weeks to settle and can recur with the next systemic trigger. A patient who expects resolution by Friday will interpret an ordinary course as a second failure.
Record the product, the batch and the site, every time. Not because your own patient will need it — because someone else's will.
Why this belongs in a training conversation
Injectable courses are organised around the appointment. They teach assessment, plane, placement and the complications that occur while you are still holding the syringe, and that emphasis is understandable, because that is where the technique lives. It is also why a practitioner can complete a full training pathway without ever being taught what a patient looks like six months later.
Ask a provider what their teaching says about the patient who returns in the spring with a swelling and no records. The answer tells you whether the course is teaching a procedure or a practice. The two are not the same thing, and only one of them is still useful when the patient in the chair was somebody else's.
Browse aesthetic medicine courses